Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?
Because of the drug’s promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.
Pediatric Cancer
PEDIATRIC CANCER ADVISOR
FEATURED CONTENT
-
-
Recent Conference Highlights New Potential Targets for Pediatric Cancer Treatments
Advances in targeted therapy for pediatric patients were presented at the AACR Special Conference on Pediatric Cancer.
PEDIATRIC CANCER NEWS
Differences in Postrelapse Mortality May be Driving Racial/Ethnic Disparities Observed in Children With Hodgkin Lymphoma
Addition of Bevacizumab to Temozolomide-Based Chemotherapy Increased OR in Children With R/R Neuroblastoma
Risk for Cardiovascular Disease Greater for Childhood Cancer Survivors
Bone Health Management Key in Childhood Cancer Survivors
Global Burden of Childhood Cancers Examined
Want to read more?
Please login or register first to view this content.
Next post in Pediatric Cancer
